Thus, our findings implied that MO-A may also regulate disorders of lipidmetabolism by CPT-1, LDLR, and PPARα, thereby decreasing the serum levels of TG andLDL-C in hyperlipidemia rats. This evidence concerns the gene LDLR and hyperlipidemia.